NCT00895713已完成2 期
Efficacy and Safety of Intramuscular Hepatitis B Virus Immune Globulin Grifols for the Prevention of Hepatitis B Virus Recurrence After Orthotopic Liver Transplantation.
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 18
- 试验地点
- 2
- 主要终点
- Mean trough serum HBsAg Ab titer
研究概览
简要总结
The purpose of this study is to determine if treatment with intramuscular hepatitis B virus immune globulin Grifols, a new specific hepatitis B immune globulin, is effective and safe for the prevention of hepatitis B virus recurrence after orthotopic liver transplantation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female.
- •Age > 18 years and < 70 years.
- •OLT recipient for HBV infection-related disease for > 18 months before inclusion in the clinical trial.
- •Serum HBsAg-positive within 3 months before transplantation.
- •Serum HBsAg-negative just before inclusion in the clinical trial.
- •Serum HbeAg-negative just before inclusion in the clinical trial.
- •Serum HBV DNA-negative by DNA PCR-amplification assay (lower detection limit 102 genomes/ml) just before inclusion in the clinical trial.
- •Continuous and interrupted prophylaxis with HBIG after an-hepatic phase as part of the subject clinical care.
- •Trough serum HBsAg Ab (HBsAg IgG) titer (immediately pre-dose) > 150 I.U./l in at least 2 consecutive determinations within last 3 months before inclusion in the clinical trail.
- •Signed informed consent.
排除标准
- •Serum HBsAg-positive just before inclusion in the clinical trial.
- •Serum HBeAg-positive within 3 months before transplantation.
- •Serum HBV DNA-positive by standard DNA hybridisation assay (lower detection limit 105 genomes/ml), or by any less sensitivity technique, within 3 months before transplantation.
- •Unknown serum HBV replication status (no data about HbeAg and HBV DNA) within 3 months before transplantation.
- •Previous recurrence of HBV in the transplanted liver defined by serum HBV DNA- positive by sensitive hybridisation (lower detection limit 105 genomes/ml) assay or any less sensitive technique, and/or serum HBeAg-positive, and/or serum HBsAg-positive.
- •Re-transplanted liver even for reasons not related to HBV infection.
- •Evidence of hepatocellular carcinoma in the transplanted liver, or metastatic disease, at time of inclusion in the clinical trial.
- •Evidence of graft rejection at time of inclusion in the clinical trial.
- •Life-expectancy less than 1 year.
- •VHC infection.
- •HIV type 1 or type 2 infection.
- •Acute HAV infection.
- •Previous treatment with i.m. HBIG Grifols within 3 months before inclusion in the clinical trial.
- •Intolerance or allergy to any i.m. HBIG Grifols containing substance (glycine, sodium chloride, sterile water for injection, homologous human immune globulin).
- •History of SAEs related to the administration of human blood-derived products.
- •History of frequent AEs, even non-serious, related to the administration of human blood-derived products.
- •Selective IgA deficiency with Abs against IgA.
- •Platelet count < 50 x 109/L.
- •Prothrombin time (PT) < 60%.
- •Activated partial thromboplastin time (APTT) ratio > 1.
- •Any haemostatic abnormality contraindicating i.m. injection according to investigator's judgement.
- •Haemoglobin < 11 g/dl.
- •Alcohol or drug abuse at the moment or within 1 year before inclusion in the clinical trial.
- •Pregnant woman or woman who is expecting to be pregnant within 1 year after inclusion in the clinical trial.
- •Breast-feeding woman.
- •Any severe acute or chronic medical, surgical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration, or may interfere with the interpretation of study results and, in the judgment of the investigator, makes the subject inappropriate for entry in this clinical trial.
- •Impossibility to donate a serum sample before the first investigational product administration.
- •Planned treatment with Ig other than i.m. HBIG Grifols within the clinical trial period.
- •Planned modification, during the clinical trial period, of the prophylactic regimen with nucleoside analogues followed by the subjects, if any, within last 3 months before inclusion in the clinical trial.
- •The subject has been previously admitted to this clinical trial.
- •Participation in other clinical trial within 3 months before study inclusion.
- •Subject's incapacity of giving consent personally.
研究组 & 干预措施
im HBIG Grifols
Experimental
干预措施: intramuscular hepatitis B virus immune globulin (Drug)
结局指标
主要结局
Mean trough serum HBsAg Ab titer
时间窗: Months 4-6
次要结局
- Safety and tolerability(7 months)
- HBV recurrence percentage in long-term OLT recipients during i.m. HBIG Grifols treatment period(Week 2 - 7 months)
- Mean trough HBsAg Ab titer(4 months)
- Individualised trough HBsAg Ab titer(Week 2 - 7 months)
- Number of subjects with serum HBV DNA-positive samples by DNA PCR-amplification assay(Week 2 - 7 months)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Intralesional Versus Intramuscular Hepatitis B Vaccine Immunotherapy for WartsIntralesional Versus Intramuscular Hepatitis B Vaccine for Multiple Common WartsNCT05326152Zagazig University75
已完成
不适用
Hepatitis B Vaccine in Patients With Inflammatory Bowel DiseaseInflammatory Bowel DiseaseNCT01531075Soroka University Medical Center91
Unknown
4 期
Adolescents' Response to Hepatitis B Vaccine Booster DoseHepatitis BNCT01341275Baylor College of Medicine400
已完成
1 期
Safety and Efficacy of a Hepatitis B Vaccine in Immunosuppressed PatientsHepatitis BNCT04199715Baylor Research Institute10
已完成
2 期
Hepatitis B Vaccination (HBV) in HIV Infected ChildrenHIV InfectionsNCT00886964The HIV Netherlands Australia Thailand Research Collaboration80